Hemant Surgical Industries share price today

Hemant Surgical Industries Ltd's share price was ₹630.00 at the close on 5 November 2026. It has been rising for 66 weeks. That is 54.6% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 10 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Hemant Surgical Industries Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 27 March 2026, it has traded between ₹243 and ₹666, and at that close it sat 92% of the way up from that low.

Over the last 7 months the share price moved +159% while the NIFTY 500 moved +5%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: number of shareholders up 59% in a year, highest quarterly profit in 8 quarters and highest quarterly revenue in 8 quarters.

1. Number of shareholders up 59% in a year

   1,202 shareholders in the September 2026 quarter, against 758 a year earlier.

2. Highest quarterly profit in 8 quarters

   Profit of ₹13 crore in the March 2026 quarter is the highest of the last 8 quarters.

3. Highest quarterly revenue in 8 quarters

   Revenue of ₹167 crore in the March 2026 quarter is the highest of the last 8 quarters.

For January to March 2026 (the quarter ended 31 March 2026), Hemant Surgical Industries reported revenue of ₹167 crore, up 187.9% from ₹58.0 crore a year earlier, and a profit of ₹13.0 crore, up 160.0% from ₹5.00 crore.

Hemant Surgical Industries results: January to March 2026 against a year earlier

The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them.

From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.

Hemant Surgical Industries closed at ₹630.00 on 5 November 2026. Its highest weekly close since March 2026 was ₹665.60 on 9 October 2026.

Hemant Surgical Industries share price: then and now

Weekly closing prices. Each change is the move from that price to the 5 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

37 weekly closes from 27 March 2026 to 5 November 2026.

5 Nov 2026: Hemant Surgical Industries closed at ₹630.00, up 9.8% on the week and down 5.3% on the month. Results for January to March 2026: Revenue up 187.9% and profit up 160.0% on a year earlier.

No. Hemant Surgical Industries Ltd paid out 0% of its profit as dividends in each of its last 9 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate (as of 5 November 2026).

Hemant Surgical Industries is on one of our India lists: Momentum stocks.

Hemant Surgical Industries Ltd earned ₹13.0 Cr of net profit in the Mar 2026 quarter, +160.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹18.0 Cr. Over 8 years profit has grown 43.5% a year on average. That is 7.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹6.0 Cr.

For the full year, FY26 profit was ₹18.0 Cr (+125.0% on the year before).

Why profit moved: revenue changed +187.9% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +46.3% and revenue +55.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

Hemant Surgical Industries Ltd reported ₹167 Cr of revenue in the Mar 2026 quarter, +187.9% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 8 years it has grown 20.8% a year on average. The last full year, FY26, came in at ₹231 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹231 Cr, +115.9% on the year before.

Recent pace: the last four quarters grew +55.2% on average, against 20.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Hemant Surgical Industries Ltd's operating margin was 9.0% in the Mar 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Over the last four quarters it has moved −4.0 percentage points. Across 9 years it has been between 4.7% and 10.0%.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

The latest quarter is within that range.

Why the margin moved: operating margin changed −3.2 percentage points on the year while gross margin changed −7.9 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years Hemant Surgical Industries Ltd's operations used more cash than they brought in, so cash conversion was −86%, a gap worth watching. In FY26 its operations used ₹32.0 Cr of cash, against ₹18.0 Cr of profit. After ₹3.0 Cr of spending on assets, free cash was −₹35.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why −86% of profit came in as cash: the cash cycle got 29 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 29 days longer. The next section looks at where the cash is stuck.

Hemant Surgical Industries Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 80 days in FY26, up from 51 days in FY21. It spent ₹44.0 Cr on assets over the last 3 years. Customers take 106 days to pay, and stock sits for 120 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹231 Cr, each day of that cycle ties up about ₹0.6 Cr, so roughly ₹51.0 Cr is tied up in the business at any time.

FY26: customers took 106 days to pay and stock sat for 120 days, about 3.9 months of sales sitting as stock, for a full cycle of 80 days, longer than FY21's 51.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 120 days. Customers pay about 106 days after that. Suppliers are paid at 146 days. Together that makes the 80-day cycle.

Spending on assets: ₹44.0 Cr over the last 3 years, against ₹4.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Hemant Surgical Industries Ltd's P/E is 54.1×, about the highest it has ever been. Its usual P/E (the middle reading) is 25.9×, over 3.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Hemant Surgical Industries Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Hemant Surgical Industries Ltd earned a ROCE of 19% in FY26. That is up from a low of 12% in FY20. Its return on capital used (ROIC) is 0.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 7.8% net margin and 0.84× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 7.8% net margin × 0.84× asset turnover × 2.00× leverage (assets divided by equity) ≈ 13.1% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 12.7% − 12.0% = +0.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

Hemant Surgical Industries Ltd had ₹50.0 Cr of borrowings against ₹137 Cr of equity in FY26, so its debt is 0.36× its equity. Its operating profit is 6 times its interest bill. Over 5 years borrowings went from ₹14.0 Cr to ₹50.0 Cr. Over the last 3 of those years it spent ₹44.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

Promoters cut their stake in Hemant Surgical Industries Ltd by 20.7 percentage points over 7 quarters, the biggest change among its owners. Promoters now own 52.8% of the company. Domestic institutions moved +15.7 points over the same period, to 19.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: −20.7 points over 7 quarters, to 52.8%; Domestic institutions: +15.7 points over 7 quarters, to 19.9%; Foreign institutions: +0.0 points over 7 quarters, to 0.0%.

Why the owners changed: promoters drove it (−20.7 points), with the other side taken by domestic institutions (+15.7 points). They reduced their stake.

For Hemant Surgical Industries Ltd, the Z-score is 2.87. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 2.87 is in the grey area, neither clearly safe nor clearly in trouble.

60.4 out of 100, rank 6 of 6 in Medical Equipment, with 48% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Hemant Surgical Industries Ltd scores 60.4 out of 100 against the 6 companies it is compared with in Medical Equipment, ranking 6. Some evidence is missing, so the score is pulled toward the middle on purpose.

The four parts add up to the total exactly: 23 + 15.2 + 9.7 + 12.5 = 60.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Hemant Surgical Industries ranks 6 of 6 Medical Equipment companies on the 4-Factor Sector Score, with 60.4 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Medical Equipment, all 6 compared on one page.

Hemant Surgical Industries is the 4th largest of 6 Medical Equipment companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Poly Medicure, Tarsons Products and Laxmi Dental. Just below it: Vasa Denticity and Prevest Denpro.

Medical Equipment companies close in size

1. Poly Medicure Ltd ₹14,692 crore
2. Tarsons Products Ltd ₹1,548 crore
3. Laxmi Dental Ltd ₹977 crore
4. Hemant Surgical Industries Ltd ₹916 crore
5. Vasa Denticity Ltd ₹754 crore
6. Prevest Denpro Ltd ₹510 crore

All 6 Medical Equipment companies, largest first

Companies close in size in other industries

1656. SEPC Ltd ₹919 crore · Project Consultancy/Turnkey
1657. BirlaNu Ltd ₹918 crore · Cement Products
1658. Hemant Surgical Industries Ltd ₹916 crore
1659. NIIT Ltd ₹915 crore · Computer Education
1660. Apex Frozen Foods Ltd ₹914 crore · FMCG - Shrimp

Sector Alpha, written by code from the published numbers. Data as of 5 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.